2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
ThePrint4h
Bridging Medical Knowledge: Jenburkt Pharmaceuticals Ltd and NIMHANS Launch First-Ever Neuropathy Masterclass Series
Jenburkt Pharmaceuticals Limited, a 40-year-old pharmaceutical organization listed on the Bombay Stock Exchange and a pioneer ...
Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
State of Alaska Department of Revenue Has $791,000 Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
State of Alaska Department of Revenue lessened its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 1.6% in the fourth quarter, HoldingsChannel reports. The fund owned 21,325 ...
KalVista Pharmaceuticals sees $1.5m stock purchase by Venrock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has attracted significant investment activity from Venrock Healthcare Capital ...
Rocket Lab USA, Inc. (RKLB) Dips More Than Broader Market: What You Should Know
The latest trading day saw Rocket Lab USA, Inc. (RKLB) settling at $28.02, representing a -0.99% change from its previous close.
Cumberland Pharmaceuticals ups common stock offering
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a pharmaceutical company with a market capitalization of $72.6 million, has ...